Collectively, these trials underscore the expanding therapeutic footprint of T-DXd—from HER2-low and ultralow hormone receptor-positive disease to HER2-positive tumors with CNS involvement—highlighting its potential as a foundational agent across molecular and clinical subtypes in advanced BC. Here, NR4A1 is linked to breast cancer.